Passage Bio, Inc. (NASDAQ:PASG – Get Free Report) shares passed above its 50-day moving average during trading on Friday. The stock has a 50-day moving average of $4.11 and traded as high as $4.25. Passage Bio shares last traded at $4.25, with a volume of 11,933 shares changing hands.
Analysts Set New Price Targets
PASG has been the subject of several recent analyst reports. Wall Street Zen cut Passage Bio from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings raised Passage Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Two investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Passage Bio currently has an average rating of “Hold” and a consensus target price of $13.25.
Get Our Latest Stock Analysis on Passage Bio
Passage Bio Trading Up 6.0%
The firm has a 50-day simple moving average of $4.11 and a two-hundred day simple moving average of $5.87. The company has a market capitalization of $13.69 million, a price-to-earnings ratio of -0.41 and a beta of 1.51.
Passage Bio (NASDAQ:PASG – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($1.47) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.47). On average, sell-side analysts forecast that Passage Bio, Inc. will post -7.75 earnings per share for the current year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Nantahala Capital Management LLC bought a new position in Passage Bio during the third quarter valued at about $573,000. Renaissance Technologies LLC lifted its position in shares of Passage Bio by 22.5% in the first quarter. Renaissance Technologies LLC now owns 133,612 shares of the company’s stock worth $1,049,000 after buying an additional 24,523 shares during the last quarter. Finally, Eversept Partners LP boosted its stake in shares of Passage Bio by 4.2% during the 1st quarter. Eversept Partners LP now owns 131,581 shares of the company’s stock worth $1,033,000 after acquiring an additional 5,351 shares in the last quarter. Institutional investors and hedge funds own 53.48% of the company’s stock.
About Passage Bio
Passage Bio is a clinical-stage biotechnology company developing gene therapies for rare, inherited central nervous system disorders. Its approach uses viral vectors to deliver genetic material intended to address the underlying causes of these diseases. The company’s lead program, PBFT02, is being developed for frontotemporal dementia associated with mutations in the GRN gene. Passage Bio has also worked on gene therapy candidates for other rare neurological conditions, including Krabbe disease and GM1 gangliosidosis.
Further Reading
- Five stocks we like better than Passage Bio
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
- Why Equinix and Digital Realty Benefit From Data Center Zoning Battles
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.
